4//SEC Filing
BONDURANT STUART 4
Accession 0001181152-11-000002
CIK 0001003124other
Filed
May 18, 8:00 PM ET
Accepted
May 19, 3:23 PM ET
Size
14.6 KB
Accession
0001181152-11-000002
Insider Transaction Report
Form 4
BONDURANT STUART
Director
Transactions
- Award
Common Stock
2011-05-18+1,139→ 21,479 total - Award
Stock Options (to buy)
2011-05-18+9,095→ 9,095 totalExercise: $28.52From: 2011-05-18Exp: 2021-05-18→ Common Stock (9,095 underlying)
Holdings
- 4,113
Stock Options (to buy)
Exercise: $34.18From: 2006-05-17Exp: 2016-05-16→ Common Stock (4,113 underlying) - 6,341
Stock Options (to buy)
Exercise: $32.67From: 2007-05-16Exp: 2017-05-16→ Common Stock (6,341 underlying) - 14,053
Stock Options (to buy)
Exercise: $19.19From: 2009-05-20Exp: 2019-05-20→ Common Stock (14,053 underlying) - 5,650
Stock Options (to buy)
Exercise: $22.98From: 2005-05-18Exp: 2015-05-17→ Common Stock (5,650 underlying) - 6,485
Stock Options (to buy)
Exercise: $41.32From: 2008-05-21Exp: 2018-05-20→ Common Stock (6,485 underlying) - 10,496
Stock Options (to buy)
Exercise: $24.52From: 2010-05-20Exp: 2020-05-20→ Common Stock (10,496 underlying)
Footnotes (1)
- [F1]Direct Holdings include an anti-dilution adjustment of 141 shares of Restricted Stock made in connection with the June 14, 2010 spin-off of Furiex Pharmaceuticals, Inc.
Documents
Issuer
PHARMACEUTICAL PRODUCT DEVELOPMENT INC
CIK 0001003124
Entity typeother
Related Parties
1- filerCIK 0001181152
Filing Metadata
- Form type
- 4
- Filed
- May 18, 8:00 PM ET
- Accepted
- May 19, 3:23 PM ET
- Size
- 14.6 KB